HRT and TRT: Separating Evidence from Marketing

Hormone therapy for women and testosterone therapy for men both spent two decades under a cloud. For women, it was one scary headline. For men, it was FDA caution that newer research has narrowed. Both now also have a wellness-marketing layer sitting on top of the real evidence, which makes it harder to tell what the science actually says versus what a clinic wants to sell you.

HRT: what the WHI scare actually found — and didn’t

In 2002, a major study called the Women’s Health Initiative made headlines with a scary-sounding claim: hormone therapy causes breast cancer and heart disease. That headline came from the trial of the estrogen-plus-progestin pill, and it is still the thing most people remember. It oversimplifies what the study showed: the separate trial of estrogen alone, in women who no longer had a uterus, found a lower rate of breast cancer.^[1] A later, deeper look at the full data found that, in the WHI follow-up, some outcomes (heart attack, and death from any cause in the estrogen-alone trial) looked more favorable in women who started in their 50s. But the authors call the heart-disease results in younger women inconclusive and say the findings do not support hormone therapy to prevent chronic disease.^[1] The original 2002 study leaned toward women a decade or more past menopause.

This is called the “timing hypothesis,” and it’s the piece that got lost in the original headline. It doesn’t mean HRT is risk-free: the WHI trials found more strokes and blood clots with hormone therapy, and more breast cancer with the combined estrogen-plus-progestin pill.^[1] It means age and how many years since menopause are part of the real question — not a blanket yes-or-no answer left over from a 20-year-old news cycle.

TRT: the FDA caution that newer research has narrowed

Testosterone replacement therapy carried a similar worry: that it might raise heart risk in men. A large study called the TRAVERSE trial tested this directly, following over 5,200 men with low testosterone who already had heart disease or were at high risk for it.^[2] The trial followed men for about 33 months and tested one product, a testosterone gel, so its results may not carry over to other forms or to longer use. Testosterone therapy performed no worse than a placebo for major heart problems — in exactly the group of men most likely to be harmed if the old worry were true. That’s a meaningfully different picture than the one behind the original FDA warning label. It isn’t a clean bill of health, though: the same trial found more atrial fibrillation, acute kidney injury, and pulmonary embolism (a blood clot in the lung) in the testosterone group,^[2] and in 2025 the FDA added a blood-pressure warning to testosterone labels.

“No worse than placebo” isn’t the same as “proven to help your heart,” though. This trial tested serious heart events in a high-risk group. It doesn’t prove the broader energy and vitality claims that wellness clinics often attach to testosterone therapy.

Where marketing outruns the evidence

• “Bioidentical” doesn’t mean safer. The word describes the molecule’s structure, not a different risk profile. Compounded “bioidentical” formulas may also lack the dosing consistency and safety monitoring that FDA-approved products go through.
• Hormone therapy isn’t an anti-aging protocol. Both bodies of evidence above are about managing symptoms and specific safety outcomes — not a general performance or longevity boost for people who don’t actually have a diagnosed deficiency.
• Skipping the diagnosis is a red flag. If a clinic offers therapy based on a single symptom checklist, without a clinician taking a full history, they’re optimizing for a sale, not a real diagnosis.

The actual decision framework

For HRT, your age and years since your final period matter, not just “do I have symptoms” — that’s the variable the timing hypothesis is built on, though the type of hormone, the dose, how it’s taken, and how long you take it matter too. For TRT, low testosterone should be confirmed with repeat morning labs plus real symptoms, following the same diagnostic standard covered in our testosterone-after-40 breakdown, before therapy is even on the table. In both cases, the real question isn’t “is this therapy good or bad.” It’s “does the evidence actually apply to someone with my age, timeline, and risk profile.” That’s a conversation for a clinician working from your full history and, for testosterone, real lab results — not a symptom quiz.

References

[1] Manson JE, et al. “Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials.” JAMA. 2013;310(13):1353-1368. DOI: 10.1001/jama.2013.278040. Finding: the authors conclude that the findings “do not support use of this therapy for chronic disease prevention, although it is appropriate for symptom management in some women,” and that “the risks of CEE+MPA [estrogen plus progestin] outweigh the benefits irrespective of a woman’s age.” Some outcomes, including heart attack, looked more favorable in women who started hormone therapy in their 50s (the “timing hypothesis”), but these were subgroup analyses the authors say should be interpreted cautiously, and the results for heart disease in younger women “remain inconclusive.” ↑︎

[2] Lincoff AM, et al. “Cardiovascular Safety of Testosterone-Replacement Therapy.” New England Journal of Medicine. 2023;389(2):107-117. DOI: 10.1056/NEJMoa2215025. Finding: in 5,246 hypogonadal men with existing/high cardiovascular risk, testosterone therapy (a 1.62% transdermal gel; mean treatment 21.7 months, follow-up 33 months) was non-inferior to placebo for major adverse cardiac events. A higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism was observed in the testosterone group. ↑︎

Kurt Greiner

Kurt is a digital strategist and IT professional blending emerging technology with practical application to help businesses and individuals streamline their digital presence. His current work focuses on the intersection of intentional living and technological resilience, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.